Quantile Health
-53%
est. 2Y upside i
Rank
#114
Sector
HealthTech, FinTech, SaaS
Est. Liquidity
~5Y
Data Quality
Data: LowQuantile Health presents a compelling equity opportunity with strong expected upside, driven by its innovative solution addressing a critical need in the rapidly growing gene therapy market.
Last updated: February 23, 2026
Quantile Health successfully scales its subscription model, achieves significant market penetration in gene therapy access, and expands into related high-cost therapies, leading to a substantial acquisition or IPO.
Quantile Health establishes a solid foothold in the gene therapy payment market, demonstrates consistent revenue growth, and secures further funding rounds, leading to a moderate acquisition.
Quantile Health faces significant regulatory hurdles, strong incumbent competition, or slower-than-expected adoption, leading to a down round or a low-value acquisition where common stock holders see minimal returns.
Preference Stack Risk
highInvestors hold $7.7M in liquidation preferences ahead of common shareholders, representing 22% of the estimated current valuation.
Dilution Risk
moderateWhile the CEO indicated a quick path to revenue and no immediate plans for additional capital, as an early-stage company, significant future dilution from subsequent funding rounds is likely for substantial scaling.
Secondary Liquidity
noneAs a Series A company, there is currently no active secondary market for employee equity, limiting liquidity options in the short term.
Utilization Management & Authorization — 1 role
Last updated: February 22, 2026
Community
Valuation Sentiment
Our model estimates -53% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.